November 21st, 2011
Prominent Dutch Cardiovascular Researcher Fired for Scientific Misconduct
Larry Husten, PHD
UPDATE (Posted Monday, November 21): Over the weekend more details emerged about this story. An executive summary of the report from the investigative committee at Erasmus MC, dated November 16, appeared on the Erasmus website. Here is a brief summary, based on help received from Google Translate, Babel Fish, and native Dutch speakers: As previously […]
November 18th, 2011
AHA.11 Concludes and Our Fellows Reflect
CardioExchange Editors, Staff, Eiman Jahangir, MD, John Ryan, MD, Amit Shah, MD, MSCR and Reva Balakrishnan, MD, MPH
Several Cardiology Fellows who are attending AHA.11 this week are blogging together on CardioExchange. The Fellows include Revathi Balakrishnan, Eiman Jahangir, John Ryan (moderator), and Amit Shah. Read the previous post here. This is their final post. See their complete coverage at the bottom of this post and in this review of our AHA coverage. Readers, […]
November 18th, 2011
AHA.11 Roundup
CardioExchange Editors, Staff
Whether you were in Orlando for AHA.11 or not, you’ll want to check out our coverage of late-breaking clinical trials, interviews with the authors of the most important research, and blogs from our fellows on the most interesting presentations at the meeting. VIEWS AND ANALYSIS ROUNDTABLE: After SATURN, What Role for Rosuvastatin? A CardioExchange Panel: […]
November 16th, 2011
Evacetrapib – The New Wonder Drug?
Amit Shah, MD, MSCR
Impressive safety and efficacy data on evacetrapib—but it’s too early give odds on whether it’s a true wonder drug or a nightmare like its fellow CETP inhibitor, torceptrapib
November 16th, 2011
Was AIM HIGH a Hit or a Miss?
Reva Balakrishnan, MD, MPH
One of the best parts of this conference has been the opportunity to hear experts on the panels dissect and interpret the data following the presentations.
November 16th, 2011
ELEVATE-TIMI 56: One New Piece of the Clopidogrel Puzzle
Larry Husten, PHD
Tripling the maintenance dose of clopidogrel in most but not all patients with a common genetic variation will lower platelet reactivity to levels achieved in patients without the variation.
November 16th, 2011
Experts Clash Over AIM-HIGH
Larry Husten, PHD
Sparks flew at the AHA press conference yesterday when the designated discussant for the AIM-HIGH trial, Australia’s Philip Barter, said that “the design was such that in no way could it test the hypothesis” that niacin therapy may be beneficial. “This trial disturbs me greatly,” he said. The trial co-principal investigator, William Boden, defended his […]
November 16th, 2011
AHA Lessons on Emotions and Heart Disease: Depressing Data but Hopeful Trends
Amit Shah, MD, MSCR
Several Cardiology Fellows who are attending AHA.11 this week are blogging together on CardioExchange. The Fellows include Revathi Balakrishnan, Eiman Jahangir, John Ryan (moderator), and Amit Shah. Read the previous post here. Check back often to learn about the biggest buzz in Orlando. The many studies and sessions devoted to depression and heart disease at AHA […]
November 16th, 2011
POWER to the People
John Ryan, MD
Several Cardiology Fellows who are attending AHA.11 this week are blogging together on CardioExchange. The Fellows include Revathi Balakrishnan, Eiman Jahangir, John Ryan (moderator), and Amit Shah. Read the previous post here. Check back often to learn about the biggest buzz in Orlando. Tuesday, I heard the presentation of the Practice-Based Opportunities for Weight Reduction (POWER) […]
November 15th, 2011
An Event, Not a Conference
Eiman Jahangir, MD
Several Cardiology Fellows who are attending AHA.11 this week are blogging together on CardioExchange. The Fellows include Revathi Balakrishnan, Eiman Jahangir, John Ryan (moderator), and Amit Shah. Read the previous post here. Check back often to learn about the biggest buzz in Orlando. This is the last day of the conference for me. While I am […]